S6K1 is a protein kinase that is sensitive to a variety of signaling inputs. It is responsible for regulating various substrates and proteins that control different oncogenic processes. In various cancers, S6K1 is shown to play a prominent role in cancer progression such as breast cancer, prostate cancer, non-small cell lung cancer (NSCLC), and brain tumors. Our lab has identified 1,3-dioxoisoindolinylamides as ATP-competitive inhibitors of the S6K1 protein.The derivatives of these compounds are synthesized in multistep synthesis in the lab and then tested against various cancer cell lines. The goal is to synthesize a compound to that is a potent and selective inhibitor of S6K1 as a cancer therapeutic.

Development of S6K1 inhibitors as therapeutics for breast cancer and prostate cancer

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.